Devendra K Hiwase

29PUBLICATIONS
190CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Medical infection agents (incl. prions)Regenerative medicine (incl. stem cells)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Oct 19, 2026
A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years.

|Sep 24, 2026
Methylation Mesa define functional regulatory elements for targeted gene activation.

|Sep 01, 2026
Infection risk in myelodysplastic syndromes is dynamic and immune driven.

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Apr 01, 2026
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee.

Christopher Armstrong, Kavita Raj, Giorgia Battipaglia

Pageof 5

Frequent Collaborators

15 joint publications

Mithun Vinod Shah

9 joint publications

Mrinal Patnaik

9 joint publications

Naseema Gangat

9 joint publications

Chung Hoow Kok